India sourcing 2026: capability beyond cost

If your sourcing strategy for India still starts with labor cost per hour, it is already two years out of date. The country's manufacturing exports reached $820.9 billion in FY2024-25 — a 5.5% increase over the prior year — and the composition of those exports tells a different story than the one most procurement teams carry. Electronics goods grew 32.47%, making India the third-largest smartphone exporter globally. Engineering goods hit a record $116.7 billion. Pharmaceuticals crossed $30.5 billion in exports, serving over 200 countries. None of these numbers are driven by wage arbitrage.

Business Today's analysis of the China+1 effect notes that multinational corporations including Apple, Samsung, and Foxconn have expanded their manufacturing footprint in India not primarily for cost reasons, but for capacity, scale, and supply chain diversification. The question for procurement leaders in 2026 is no longer "is India cheaper than China?" — the answer to which varies by category and has been narrowing for years. The question is "what capabilities can India deliver that other markets cannot at comparable quality and reliability?"

---

Electronics: the fastest ramp in emerging-market manufacturing

India's electronics manufacturing output grew from approximately $26 billion in FY2021 to approximately $63 billion in FY2025, a 2.4x increase in four years driven by the Production Linked Incentive (PLI) scheme for large-scale electronics. ET Edge Insights reports that electronics became India's third-largest and fastest-growing export category by 2024-25, climbing from seventh place in 2021-22. In just the first half of FY2026, electronics exports reached approximately $22.2 billion — up 42% year-on-year.

The component ecosystem, however, still trails the assembly ramp. The government approved the Electronics Components Manufacturing Scheme (ECMS) in March 2025 with a ₹22,919 crore outlay targeting MLPCBs, camera and display modules, lithium-ion cells, and passive components. IBEF data shows 75 ECMS applications approved by early 2026, with expected investment of ₹61,671 crore and 65,040 direct jobs distributed across Andhra Pradesh, Karnataka, Tamil Nadu, Uttar Pradesh, and Maharashtra. The EMC 2.0 cluster program is expected to mobilize ₹1.46 lakh crore in investment and create approximately 180,000 jobs.

"Electronics are now the country's third-largest and fastest-growing export category, climbing from seventh place in 2021–22 to third in 2024–25. In just the first half of FY26, electronics exports touched about USD 22.2 billion, up 42% year-on-year." — ET Edge Insights

The KPMG assessment flags a "scale without depth" risk — strong in assembly and final-device manufacturing, weaker in high-certification segments like automotive ECUs and industrial power electronics. For procurement teams, this means India is a proven source for consumer electronics, telecom gear, and mid-complexity PCBA, but still maturing for mission-critical components where reliability certification timelines run 18-24 months.

---

Pharmaceuticals: from generic reliance to API self-sufficiency

India exported approximately ₹2.62 lakh crore ($30.5 billion) in pharmaceuticals in FY2024-25, a 10% year-on-year increase, and the composition is shifting. India Briefing reports that under the pharma PLI, sales over the first three years exceeded ₹2.66 trillion, including ₹1.7 trillion in exports. The critical development for global buyers is that India moved from a net importer of bulk drugs (₹19.3 billion deficit in FY2021-22) to a net exporter (₹22.8 billion surplus by FY2024-25).

This matters because upstream API dependency on China has been the single largest vulnerability in global pharmaceutical supply chains. The API and Key Starting Materials (KSM) PLI achieved approximately 83.7% domestic value addition for covered products by FY2024-25. For procurement organizations managing pharma supply chains, India now offers a genuinely alternative source for APIs that were previously China-exclusive — Penicillin-G, paracetamol, and select antibiotic starting materials among them.

Sourcing from India's pharma sector no longer requires accepting trade-offs on regulatory familiarity. Indian manufacturers supply US-FDA approved facilities, EU GMP-certified plants, and WHO-prequalified production lines. The capability question is not "can they meet the standard" but "which cluster has the specific capability your category needs" — an important distinction for procurement category managers who may not know that Hyderabad specializes in injectables while Gujarat concentrates on APIs and Ahmedabad excels in formulations.

---

Automotive components and engineering: the infrastructure multiplier

India's engineering goods exports reached a record $116.7 billion in FY2024-25, driven by industrial machinery, iron and steel products, and electrical machinery. Automotive components — castings, forgings, transmission parts, wiring harnesses — remain a significant sub-segment. The auto-components PLI attracted approximately ₹29,500 crore in investment and generated roughly 45,000 jobs by early 2025.

What changes the calculus for procurement teams evaluating India for engineered components is infrastructure, specifically the Dedicated Freight Corridors (DFCs). As of March 2025, 96.4% of the 2,843 km DFC network was operational. The World Bank reports that freight speeds on DFCs have doubled to 40-60 km/h, containers that once took more than a day and a half to reach Delhi from western India now arrive in less than 24 hours, and daily freight train counts rose from 241 in FY2024 to 403 in FY2025.

The National Logistics Policy targets reducing logistics costs from 13-15% of GDP to 8% by 2030. India's World Bank Logistics Performance Index ranking improved from 44 in 2018 to 38 in 2023. For a procurement team comparing total landed cost of an auto component from India versus Southeast Asia, the improving logistics infrastructure directly narrows the lead time and reliability gap.

---

The PLI effect: policy as a capability accelerator

The PLI scheme, launched in 2020 across 14 sectors, is the most significant industrial policy shift in India's manufacturing history. As of December 2025, Grip Invest reports 836 approved applications with realized investments of approximately ₹2.16 lakh crore ($26 billion) and incremental production and sales exceeding ₹18.7 lakh crore ($225 billion). Over 1.26 million direct and indirect jobs have been created.

The distribution matters for sourcing decisions. Electronics and pharmaceuticals account for approximately 70% of PLI outlay disbursed in FY2025, meaning those sectors have the deepest recent investment in capacity and quality systems. The PLI for automobiles and auto components (₹25,938 crore outlay) and ACC batteries is fueling EV drivetrain investment, with PLI-linked EV and advanced automotive sales reaching ₹32,879 crore in FY2025-26.

For procurement teams evaluating a new country source, the PLI data provides a useful proxy for supplier readiness. A supplier operating in a sector with high PLI penetration has likely invested in capacity expansion, quality certification, and workforce training as a condition of scheme participation. This does not replace a supplier audit, but it narrows the search universe.

---

Regional specialization: where to source what

India's manufacturing geography is more regionally specialized than many procurement teams assume. India Data Map shows Gujarat dominating manufacturing exports at $146.5 billion, driven by chemicals, pharma, and textiles. Maharashtra ranks second at $72.5 billion, with a diversified base in automobiles, engineering, and chemicals. Karnataka ($27.9 billion) is rising on electronics and machine tools. Tamil Nadu remains strong in automobiles and textiles.

For procurement teams running RFx processes, this geographic specialization means supplier selection can be optimized not just for capability but for logistics connectivity. A pharma API sourced from Gujarat benefits from proximity to Mundra and Kandla ports. An electronic component from Tamil Nadu has direct access to the Chennai port and the Chennai-Bengaluru industrial corridor. These logistics advantages compound into real total landed cost differences.

---

What this means for procurement teams in 2026

Five specific actions for sourcing organizations evaluating India as a procurement destination:

1. Re-evaluate your category sourcing strategy for India on capability, not cost. For electronics, pharma APIs, auto components, and engineering goods, India's PLI-backed capacity and infrastructure improvements have shifted the value proposition. Run a total capability assessment — quality certifications, delivery reliability, export track record — for each category, not just a cost comparison. Expected outcome: a new sourcing candidate in at least one category, or a confirmed decision to reallocate volume from incumbent sources.
2. Run a regional cluster analysis before supplier shortlisting. A supplier in Gujarat cannot be compared directly to one in Tamil Nadu — the cost structures, logistics connectivity, and infrastructure quality differ materially. Map your category requirements to the strongest regional cluster and set expectations accordingly. Expected outcome: more accurate landed cost estimates and lead time projections.
3. Verify PLI participation as a supplier readiness indicator. PLI-participating suppliers have undergone government vetting, capacity verification, and production tracking. This does not replace audit, but it provides a baseline. Ask for the supplier's PLI application number and production reports. Expected outcome: reduced supplier discovery risk in high-PLI sectors (electronics, pharma, auto).
4. Include DFC connectivity in logistics planning. For suppliers located along the Eastern and Western DFC corridors, inland transit times are now materially shorter and more predictable than two years ago. Ask suppliers for their nearest DFC connection point and model lead time using DFC-based transit rather than road-only assumptions. Expected outcome: 20-40% reduction in modeled inland transit time for DFC-connected suppliers.
5. Build a pharma API diversification plan using India as the primary alternative source. India's transition to a net exporter of bulk drugs represents a structural shift in global pharma supply chains. For any API where China currently supplies >50% of your volume, identify the Indian alternative with the appropriate regulatory approvals. Expected outcome: a defensible second-source plan for the top 5 APIs by spend within one quarter.

---

Frequently asked questions

---